摘要
Background: Plasma-based biomarkers would be potential biomarkers for early diagnosis of Alzheimer's disease (AD) because they are more available and cost-effective than cerebrospinal fluid (CSF) or neuroimaging. Therefore, we aimed to evaluate whether phosphorylated tau181 (p-tau181) in plasma could be an accurate AD predictor. @@@ Methods: Participants from the ADNI database included 185 cognitively unimpaired subjects with negative A beta (CU-), 66 subjects with pre-clinical AD (CU with positive A beta), 164 subjects with mild cognitive impairment with negative A beta (MCI-), 254 subjects with prodromal AD (MCI with positive A beta), and 98 subjects with dementia. Multiple linear regression models, linear mixed-effects models, and local regression were used to explore cross-sectional and longitudinal associations of plasma p-tau181 with cognition, neuroimaging, or CSF biomarkers adjusted for age, sex, education, and APOE genotype. Besides, Kaplan-Meier and adjusted Cox-regression model were performed to predict the risk of progression to dementia. Receiver operating characteristic analyses were performed to evaluate the predictive value of p-tau181. @@@ Results: Plasma p-tau181 level was highest in AD dementia, followed by prodromal AD and pre-clinical AD. In pre-clinical AD, plasma p-tau181 was negatively associated with hippocampal volume (beta = -0.031, p-value = 0.017). In prodromal AD, plasma p-tau181 was associated with decreased global cognition, executive function, memory, language, and visuospatial functioning (beta range -0.119 to -0.273, p-value < 0.05) and correlated with hippocampal volume (beta = -0.028, p-value < 0.005) and white matter hyperintensity volume (WMH) volume (beta = 0.02, p-value = 0.01). In AD dementia, increased plasma p-tau181 was associated with worse memory. In the whole group, baseline plasma p-tau181 was significantly associated with longitudinal increases in multiple neuropsychological test z-scores and correlated with AD-related CSF biomarkers and hippocampal volume (p-value < 0.05). Meanwhile, CU or MCI with high plasma p-tau181 carried a higher risk of progression to dementia. The area under the curve (AUC) of the adjusted model (age, sex, education, APOE genotype, and plasma p-tau181) was 0.78; that of additionally included CSF biomarkers was 0.84. @@@ Conclusions: Plasma p-tau181 level is related to multiple AD-associated cognitive domains and AD-related CSF biomarkers at the clinical stages of AD. Moreover, plasma p-tau181 level is related to the change rates of cognitive decline and hippocampal atrophy. Thus, this study confirms the utility of plasma p-tau181 as a non-invasive biomarker for early detection and prediction of AD.
学科与关键词
- Brain Gray Matter Volume Mediated the Correlation Between Plasma P-Tau and Cognitive Function of Early Alzheimer's Disease in China: A Cross-Sectional Observational StudyWan, Ke; Yin, Wenwen; Tang, Yating; Zhu, Wenhao; Wang, Zhiqiang; Zhou, Xia; Zhang, Wei; Zhang, Cun; Yu, Xianfeng; Zhao, Wenming; Li, Chenchen; Zhu, Xiaoqun; Sun, Zhongwu*JOURNAL OF ALZHEIMERS DISEASE, 2023, 92(1): 81-93.被引 1
- 18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's diseaseMattsson, Niklas*; Scholl, Michael; Strandberg, Olof; Smith, Ruben; Palmqvist, Sebastian; Insel, Philip S.; Hgerstrom, Douglas; Ohlsson, Tomas; Zetterberg, Henrik; Jogi, Jonas; Blennow, Kaj; Hansson, Oskar*EMBO Molecular Medicine, 2017, 9(9): 1212-1223.被引 145
- Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer's diseaseWang, Jia; Zhou, Fang; Xiong, Chang-E; Wang, Gui-Ping; Chen, Lin-Wanyue; Zhang, Yu -Tong; Qi, Shi-Ge; Wang, Zhi-Hui; Mei, Can; Xu, Yu-Jia; Zhan, Jian-Bo*; Cheng, Jing*Aging-US, 2023, 15(18): 9464-9478.被引 1
